Enhancing the QUAlity and Transparency Of health Research
Search for reporting guidelines
Use your browser's Back button to return to your search results
REporting recommendations for tumour MARKer prognostic studies (REMARK)
| Reporting guideline provided for? (i.e. exactly what the authors state in the paper) |
Tumour marker prognostic studies |
| Full bibliographic reference | McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer. 2005;93(4):387-391. |
| Language | English |
| PubMed ID | 16106245 |
| Relevant URLs (full-text if available) |
Download the REMARK checklist (Word) for tumour marker prognostic studies. |
| Explanation and elaboration papers | Abridged explanation and elaboration Sauerbrei W, Taube SE, McShane LM, Cavenagh MM, Altman DG. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): An Abridged Explanation and Elaboration. J Natl Cancer Inst. 2018. PMID: 29873743 Detailed explanation and elaboration Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. BMC Med. 2012;10:51. PMID: 22642691 PLoS Med. 9(5):e1001216. Link to full-text |
| Reporting guideline acronym | REMARK |
| Study design | Diagnostic and prognostic studies, Observational studies |
| Clinical area | Genetics, Oncology |
| Applies to the whole report or to individual sections of the report? | Whole report |
| Other relevant research (i.e. research regarding the guideline's effectiveness usability, impact etc.) |
REMARK profile to aid structured reporting Sauerbrei W, Haeussler T, Balmford J, Huebner M. Structured reporting to improve transparency of analyses in prognostic marker studies. BMC Med. 2022;20(1):184. PMID: 35546237 |
| Record last updated on | May 16, 2022 |